HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ: PRAX) and maintained a price target of $120.01. This endorsement reflects the firm's confidence in the company's future performance.